8:04 AM
 | 
Jun 29, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Summit discontinues DMD program after Phase II miss

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the Phase II PhaseOut DMD trial to treat Duchenne muscular dystrophy (DMD).

PhaseOut DMD enrolled 40 DMD patients ages 5-10. Ezutromid missed the open-label, U.S. and U.K. trial's...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >